Ganciclovir Antiviral Therapy in Advanced Idiopathic Pulmonary Fibrosis: An Open Pilot Study
Table 1
Patient demographics.
Patient
Sex
Age
Method of diagnosis*
Forced vital capacity (L)
Total lung capacity (L)
DLCO (mL/min/mmHg)
Response to treatment
Outcome (after treatment)
1
M
66
Biopsy/HRCT
2.05
3.69
3.07
Responder
Dead (9 months)
2
F
51
HRCT
1.21
2.11
#
Responder
Alive
3
F
41
Biopsy/HRCT
1.63
3.3
3.93
Responder
Alive
4
F
71
HRCT
2.09
3.59
5.61
Responder
Dead (30 mths)
5
F
62
HRCT*
0.71
#
#
Responder
Transplanted (2 mths)
6
M
60
HRCT
2.52
4.18
4.3
Nonresponder
Dead (5 mths)
7
F
66
HRCT
1.07
2.89
2.94
Nonresponder
Dead (7 mths)
8
F
60
HRCT
1.75
3.02
1.39
Nonresponder
Dead (6 mths)
9
M
57
HRCT*
1.72
2.99
2.58
Nonresponder
Transplanted (4 mths)
10
F
50
HRCT*
1.43
2.59
#
Responder
Transplanted (4 mths)
11
F
46
HRCT*
1.25
2.39
3.9
Responder
Transplanted (11 mths)
12
M
61
HRCT*
1.88
3.86
3.3
Nonresponder
Transplanted (2 mths)
13
F
73
HRCT
1.60
3.17
3.2
Responder
Dead (9 mths)
14
M
47
Biopsy/HRCT
3.35
#
#
Responder
Alive
*All patients had a diagnostic HRCT. Three patients had diagnostic histology concurrently by VATS (video assisted thoracoscopy) and a further five patients had the histological confirmation confirmed in the explanted lung after transplantation. #Patients were unable to perform testing.
